Seattle-based biotechnology company VentiRx revealed it has raised $19.3 million in financing in an SEC filing this week. The company has raised a total of $50 million since opening this round of financing in 2010.
The company focuses on developing immunotherapies for the treatment of cancer and inflammatory diseases.
Frazier Healthcare Ventures, Arch Venture Partners, Domain Associates, MedImmune Ventures and Celgene Corp. are all investors in the company, according to a spokeswoman for VentiRx.
Help employers find you! Check out all the jobs and post your resume.
